Exelixis Moves Into Metabolic Disease

genomeweb
360dx

Exelixis Moves Into Metabolic Disease

Jul 26, 2001

NEW YORK, July 26 – Exelixis is expanding its internal drug discovery efforts into metabolic diseases, including cardiovascular disease, diabetes, and obesity, the company said Thursday.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Diagenode Acquires Epigenetics Firm Nxt-Dx
New Products Posted to GenomeWeb: Helomics, Empirical Bioscience, IncellDx, More
Signature Science Wins $2.3M Government Contract to Develop Forensic Tool
Illumina Prices Senior Notes Offering
Canadian Government, Industry Invest C$21M in Genomic Applications Program
CoreBiome Awarded $220K Translational Product Development Grant

The Scan

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Main menu